United States - English - NLM (National Library of Medicine)

alcon - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - solution/ drops - 5.6 mg in 1 ml - betoptic ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. it may be used alone or in combination with other anti-glaucoma drugs. in clinical studies betoptic was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. however, caution should be used in treating patients with severe reactive airway disease or a history of asthma. hypersensitivity to any component of this product. betoptic ophthalmic solution is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular block, cardiogenic shock, or patients with overt cardiac failure.

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - betaxolol hydrochloride 2.8 mg in 1 ml - betoptic s® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension. betoptic s is contraindicated in patients with: - sinus bradycardia - greater than a first degree atrioventricular (av) block - cardiogenic shock - patients with overt cardiac failure - hypersensitivity to any component of this product risk summary there are no adequate and well-controlled studies of betoptic s administration in pregnant women to inform a drug-associated risk. there are limited data with the use of betaxolol eye drops in pregnant women. epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta-blockers are administered by the oral route. in animal reproductive studies, no drug-induced maternal toxicity or teratogenicity was observed at clinically relevant doses (see data) . because animal reproductive studies are not always

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride, quantity: 5.6 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium hydroxide; sodium chloride; hydrochloric acid; disodium edetate; purified water - indications as at 23 march 1999: betoptic 0.5% have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angular glaucoma. betoptic eye drops 0.5% may be used alone or in combination with other iop-lowering medication.

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - kit - betoptic® pilo ophthalmic suspension is indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension who are insufficiently responsive to betoptic® -s (failed to achieve target iop determined after multiple measurements over time). it is not known whether betoptic® pilo is equivalent in iop lowering efficacy to the administration of betoptic® -s 0.25% and pilocarpine 1.75% dosed separately. it is not known whether betoptic® pilo is equivalent to other beta-blockers given in combination with pilocarpine. betoptic® pilo ophthalmic suspension is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular heart block, cardiogenic shock or patients with overt cardiac failure. betoptic® pilo ophthalmic suspension is also contraindicated in conditions where miosis is undesirable (e.g., peripheral anterior synechia, trauma, acute inflammatory disease of the anterior chamber, glaucoma occurring or persisting

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - betoptic s® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension. betoptic s is contraindicated in patients with: - sinus bradycardia - greater than a first degree atrioventricular (av) block - cardiogenic shock - patients with overt cardiac failure - hypersensitivity to any component of this product risk summary there are no adequate and well-controlled studies of betoptic s administration in pregnant women to inform a drug-associated risk. there are limited data with the use of betaxolol eye drops in pregnant women. epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta-blockers are administered by the oral route. in animal reproductive studies, no drug-induced maternal toxicity or teratogenicity was observed at clinically relevant doses (see data) . because animal reproductive studies are not always

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - betaxolol hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - betaxolol hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - betaxolol hydrochloride 0.56% equivalent to betaxolol 5 mg/ml;  ;  ;   - eye drops, solution - 0.5 % - active: betaxolol hydrochloride 0.56% equivalent to betaxolol 5 mg/ml       excipient: benzalkonium chloride as 50%soln + 5% overage. equiv. to 0.1mg/ml disodium edetate dihydrate hydrochloric acid purified water sodium chloride sodium hydroxide - the treatment of ocular hypertension or chronic open angle glaucoma. may be used alone or in combination with other iop-lowering medication.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - betaxolol hydrochloride 0.28%{relative} equivalent to to betaxolol 2.5 mg/ml - eye drops, suspension - 0.25% w/v - active: betaxolol hydrochloride 0.28%{relative} equivalent to to betaxolol 2.5 mg/ml excipient: amberlite benzalkonium chloride as 50% soln + 5% overage. equiv. to 0.1mg/ml carbomer disodium edetate dihydrate hydrochloric acid mannitol purified water sodium hydroxide - the treatment of ocular hypertension or chronic open angle glaucoma. may be used alone or in combination with other iop-lowering medication.